サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1763206

止血診断の世界市場

Hemostasis Diagnostics

出版日
ページ情報
英文 173 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.69円
止血診断の世界市場
出版日: 2025年07月07日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 173 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

止血診断の世界市場は2030年までに32億米ドルに到達

2024年に24億米ドルと推定される止血診断の世界市場は、分析期間2024-2030年にCAGR 4.8%で成長し、2030年には32億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるプロトロンビン試験時間（PT）は、CAGR 4.6%を記録し、分析期間終了までに13億米ドルに達すると予測されます。Dダイマーセグメントの成長率は、分析期間中CAGR 5.7%と推定されます。

米国市場は6億3,670万米ドルと推定、中国はCAGR 8.4％で成長すると予測

米国の止血診断市場は、2024年に6億3,670万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに7億3,630万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは8.4%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.7%と4.8%と予測されています。欧州では、ドイツがCAGR 2.2%で成長すると予測されています。

世界の止血診断市場- 主要動向と促進要因のまとめ

患者ケアにおける止血診断の役割とは？

止血診断は、血友病、深部静脈血栓症、von Willebrand病などの血液凝固障害の評価に極めて重要です。これらの診断は、様々な凝固因子、血小板機能、凝固時間を測定し、出血性疾患の管理や血栓性イベントの予防に役立つ貴重な情報を提供します。止血検査はまた、手術前の評価や抗凝固療法のモニタリングにも不可欠であり、正確でタイムリーな結果が患者の安全にとって重要です。出血性疾患は、特に高齢化が進むにつれてますます蔓延しており、止血診断は日常診療と救急の両方の場面でますます重要になってきています。

なぜ止血診断の技術的進歩が重要なのか？

技術の進歩は止血診断の精度と効率を高めています。自動凝固分析装置や粘弾性検査のような技術革新は、出血リスクの管理に不可欠な、より迅速で詳細な評価を可能にしています。また、ポイントオブケア機器も普及しつつあり、ヘルスケアプロバイダーは外来で止血検査を実施し、結果をリアルタイムで受け取ることができます。これらの進歩は診断のスピードと精度を向上させ、特に重篤な状況において、患者の予後改善と治療モニタリングに役立っています。

ヘルスケア規制は止血検査にどのような影響を与えているか？

正確で信頼性の高い検査は患者の安全にとって不可欠であるため、ヘルスケア規制は止血診断において重要な役割を果たしています。規制機関は検査の信頼性を確保するため、診断機器や試薬に厳格な品質基準を課しています。これらの基準の遵守は必須であり、ヘルスケアプロバイダーは規制要件を満たす高度な診断機器への投資を促しています。このようなコンプライアンス重視の姿勢が、安全で効果的な患者ケアを保証する、認証された高品質の止血診断への需要を促進しています。

止血診断市場の成長の原動力は？

止血診断市場の成長の原動力は、出血性疾患管理に対する需要の増加、診断機器の技術進歩、厳格なヘルスケア規制です。出血性疾患の有病率が上昇するにつれ、正確でタイムリーな診断に対する需要が高まっています。技術革新により診断の精度と効率が向上しており、これらの検査は患者の安全性と効果的な治療に不可欠となっています。高品質の診断を義務付ける規制基準が市場の成長をさらに後押ししており、止血診断は患者ケアの重要な要素となっています。

セグメント

検査タイプ（プロトロンビン検査時間（PT）、Dダイマー、フィブリノゲン、活性化部分トロンボプラスチン時間）、エンドユーザー（病院、診断センター、その他のエンドユーザー）

調査対象企業の例

  • Abbott Laboratories
  • Alere, Inc.
  • Danaher Corporation
  • F. Hoffmann-La Roche AG
  • Grifols SA
  • Instrumentation Laboratory
  • Nihon Kohden Corporation
  • Siemens Healthineers
  • Sysmex Corporation
  • Thermo Fisher Scientific, Inc.

AIインテグレーション

当社は、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP16458

Global Hemostasis Diagnostics Market to Reach US$3.2 Billion by 2030

The global market for Hemostasis Diagnostics estimated at US$2.4 Billion in the year 2024, is expected to reach US$3.2 Billion by 2030, growing at a CAGR of 4.8% over the analysis period 2024-2030. Prothrombin Test Time (PT), one of the segments analyzed in the report, is expected to record a 4.6% CAGR and reach US$1.3 Billion by the end of the analysis period. Growth in the D Dimer segment is estimated at 5.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$636.7 Million While China is Forecast to Grow at 8.4% CAGR

The Hemostasis Diagnostics market in the U.S. is estimated at US$636.7 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$736.3 Million by the year 2030 trailing a CAGR of 8.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.7% and 4.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.2% CAGR.

Global Hemostasis Diagnostics Market - Key Trends & Drivers Summarized

What Role Do Hemostasis Diagnostics Play in Patient Care?

Hemostasis diagnostics are crucial for assessing blood clotting disorders, such as hemophilia, deep vein thrombosis, and von Willebrand disease. These diagnostics measure various clotting factors, platelet function, and coagulation time, providing valuable information for managing bleeding disorders and preventing thrombotic events. Hemostasis testing is also essential for pre-surgical assessments and monitoring anticoagulant therapy, where accurate and timely results are critical for patient safety. As bleeding disorders become more prevalent, particularly with aging populations, hemostasis diagnostics are increasingly important in both routine care and emergency settings.

Why Are Technological Advancements in Hemostasis Diagnostics Important?

Technological advancements are enhancing the accuracy and efficiency of hemostasis diagnostics. Innovations like automated coagulation analyzers and viscoelastic testing are enabling faster, more detailed assessments, which are crucial in managing bleeding risks. Point-of-care devices are also gaining popularity, allowing healthcare providers to perform hemostasis tests in outpatient settings and receive results in real time. These advancements help improve diagnostic speed and accuracy, supporting better patient outcomes and treatment monitoring, particularly in critical care situations.

How Are Healthcare Regulations Impacting Hemostasis Testing?

Healthcare regulations play a significant role in hemostasis diagnostics, as accurate and reliable testing is essential for patient safety. Regulatory agencies enforce strict quality standards for diagnostic instruments and reagents to ensure test reliability. Compliance with these standards is mandatory, prompting healthcare providers to invest in advanced diagnostic equipment that meets regulatory requirements. This focus on regulatory compliance is driving demand for certified, high-quality hemostasis diagnostics, ensuring safe and effective patient care.

What Drives the Growth of the Hemostasis Diagnostics Market?

The growth in the hemostasis diagnostics market is driven by increased demand for bleeding disorder management, technological advancements in diagnostic devices, and strict healthcare regulations. As the prevalence of bleeding disorders rises, there is growing demand for accurate and timely diagnostics. Technological innovations are enhancing diagnostic precision and efficiency, making these tests essential for patient safety and effective treatment. Regulatory standards that mandate high-quality diagnostics are further supporting market growth, positioning hemostasis diagnostics as a critical component of patient care.

SCOPE OF STUDY:

The report analyzes the Hemostasis Diagnostics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Test Type (Prothrombin Test Time (PT), D Dimer, Fibrinogen, Activated Partial Thromboplastin Time); End-Use (Hospitals, Diagnostic Centers, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 46 Featured) -

  • Abbott Laboratories
  • Alere, Inc.
  • Danaher Corporation
  • F. Hoffmann-La Roche AG
  • Grifols SA
  • Instrumentation Laboratory
  • Nihon Kohden Corporation
  • Siemens Healthineers
  • Sysmex Corporation
  • Thermo Fisher Scientific, Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Hemostasis Diagnostics - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
    • Global Economic Update
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Demand for Hemostasis Testing in Surgical and Critical Care
    • Growth in Point-of-Care Hemostasis Testing Solutions for Rapid Results
    • Advancements in Coagulation Analyzers for Enhanced Precision
    • Expansion of Hemostasis Diagnostics in Hemophilia and Thrombosis
    • Higher Demand for Personalized Hemostasis Testing Solutions
    • Development of Automated Hemostasis Analyzers in Clinical Labs
    • Growth in Demand for Anti-Coagulation Monitoring Solutions
    • Increased Adoption of AI-Driven Hemostasis Data Analytics
    • Expansion of Testing in Pre-Surgical and Critical Care Settings
    • Rising Use of Hemostasis Diagnostics in Blood Disorder Management
    • Growth of Home Testing Options for Hemostasis Monitoring
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 3: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 4: World Hemostasis Diagnostics Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Hemostasis Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Hemostasis Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Prothrombin Test Time (PT) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Prothrombin Test Time (PT) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Prothrombin Test Time (PT) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for D Dimer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for D Dimer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for D Dimer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Fibrinogen by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Fibrinogen by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Fibrinogen by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Activated Partial Thromboplastin Time by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Activated Partial Thromboplastin Time by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Activated Partial Thromboplastin Time by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Diagnostic Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Diagnostic Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Diagnostic Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Hemostasis Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: USA 15-Year Perspective for Hemostasis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 29: USA Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: USA 15-Year Perspective for Hemostasis Diagnostics by Test Type - Percentage Breakdown of Value Sales for Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: Canada 15-Year Perspective for Hemostasis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: Canada 15-Year Perspective for Hemostasis Diagnostics by Test Type - Percentage Breakdown of Value Sales for Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time for the Years 2015, 2025 & 2030
  • JAPAN
    • Hemostasis Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: Japan 15-Year Perspective for Hemostasis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Japan 15-Year Perspective for Hemostasis Diagnostics by Test Type - Percentage Breakdown of Value Sales for Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time for the Years 2015, 2025 & 2030
  • CHINA
    • Hemostasis Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 44: China Recent Past, Current & Future Analysis for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: China 15-Year Perspective for Hemostasis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 47: China Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: China 15-Year Perspective for Hemostasis Diagnostics by Test Type - Percentage Breakdown of Value Sales for Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time for the Years 2015, 2025 & 2030
  • EUROPE
    • Hemostasis Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Europe 15-Year Perspective for Hemostasis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Hemostasis Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Europe 15-Year Perspective for Hemostasis Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Europe 15-Year Perspective for Hemostasis Diagnostics by Test Type - Percentage Breakdown of Value Sales for Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time for the Years 2015, 2025 & 2030
  • FRANCE
    • Hemostasis Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 59: France Recent Past, Current & Future Analysis for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: France 15-Year Perspective for Hemostasis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: France 15-Year Perspective for Hemostasis Diagnostics by Test Type - Percentage Breakdown of Value Sales for Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time for the Years 2015, 2025 & 2030
  • GERMANY
    • Hemostasis Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Germany 15-Year Perspective for Hemostasis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Germany 15-Year Perspective for Hemostasis Diagnostics by Test Type - Percentage Breakdown of Value Sales for Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Italy 15-Year Perspective for Hemostasis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Italy 15-Year Perspective for Hemostasis Diagnostics by Test Type - Percentage Breakdown of Value Sales for Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Hemostasis Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 77: UK Recent Past, Current & Future Analysis for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: UK 15-Year Perspective for Hemostasis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: UK 15-Year Perspective for Hemostasis Diagnostics by Test Type - Percentage Breakdown of Value Sales for Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Spain 15-Year Perspective for Hemostasis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Spain 15-Year Perspective for Hemostasis Diagnostics by Test Type - Percentage Breakdown of Value Sales for Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Russia 15-Year Perspective for Hemostasis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Russia 15-Year Perspective for Hemostasis Diagnostics by Test Type - Percentage Breakdown of Value Sales for Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Rest of Europe 15-Year Perspective for Hemostasis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Rest of Europe 15-Year Perspective for Hemostasis Diagnostics by Test Type - Percentage Breakdown of Value Sales for Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Hemostasis Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 15-Year Perspective for Hemostasis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Hemostasis Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 15-Year Perspective for Hemostasis Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 15-Year Perspective for Hemostasis Diagnostics by Test Type - Percentage Breakdown of Value Sales for Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Hemostasis Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Australia 15-Year Perspective for Hemostasis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Australia 15-Year Perspective for Hemostasis Diagnostics by Test Type - Percentage Breakdown of Value Sales for Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time for the Years 2015, 2025 & 2030
  • INDIA
    • Hemostasis Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 116: India Recent Past, Current & Future Analysis for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: India 15-Year Perspective for Hemostasis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 119: India Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: India 15-Year Perspective for Hemostasis Diagnostics by Test Type - Percentage Breakdown of Value Sales for Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: South Korea 15-Year Perspective for Hemostasis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: South Korea 15-Year Perspective for Hemostasis Diagnostics by Test Type - Percentage Breakdown of Value Sales for Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 15-Year Perspective for Hemostasis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 15-Year Perspective for Hemostasis Diagnostics by Test Type - Percentage Breakdown of Value Sales for Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Hemostasis Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Latin America 15-Year Perspective for Hemostasis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Hemostasis Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Latin America 15-Year Perspective for Hemostasis Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Latin America 15-Year Perspective for Hemostasis Diagnostics by Test Type - Percentage Breakdown of Value Sales for Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Argentina 15-Year Perspective for Hemostasis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Argentina 15-Year Perspective for Hemostasis Diagnostics by Test Type - Percentage Breakdown of Value Sales for Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Brazil 15-Year Perspective for Hemostasis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Brazil 15-Year Perspective for Hemostasis Diagnostics by Test Type - Percentage Breakdown of Value Sales for Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Mexico 15-Year Perspective for Hemostasis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Mexico 15-Year Perspective for Hemostasis Diagnostics by Test Type - Percentage Breakdown of Value Sales for Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Rest of Latin America 15-Year Perspective for Hemostasis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Rest of Latin America 15-Year Perspective for Hemostasis Diagnostics by Test Type - Percentage Breakdown of Value Sales for Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Hemostasis Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Middle East 15-Year Perspective for Hemostasis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Hemostasis Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Middle East 15-Year Perspective for Hemostasis Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Middle East 15-Year Perspective for Hemostasis Diagnostics by Test Type - Percentage Breakdown of Value Sales for Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Iran 15-Year Perspective for Hemostasis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Iran 15-Year Perspective for Hemostasis Diagnostics by Test Type - Percentage Breakdown of Value Sales for Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Israel 15-Year Perspective for Hemostasis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Israel 15-Year Perspective for Hemostasis Diagnostics by Test Type - Percentage Breakdown of Value Sales for Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Saudi Arabia 15-Year Perspective for Hemostasis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Saudi Arabia 15-Year Perspective for Hemostasis Diagnostics by Test Type - Percentage Breakdown of Value Sales for Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: UAE 15-Year Perspective for Hemostasis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: UAE 15-Year Perspective for Hemostasis Diagnostics by Test Type - Percentage Breakdown of Value Sales for Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Rest of Middle East 15-Year Perspective for Hemostasis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Rest of Middle East 15-Year Perspective for Hemostasis Diagnostics by Test Type - Percentage Breakdown of Value Sales for Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time for the Years 2015, 2025 & 2030
  • AFRICA
    • Hemostasis Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Hemostasis Diagnostics by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Africa 15-Year Perspective for Hemostasis Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Hemostasis Diagnostics by Test Type - Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Africa 15-Year Perspective for Hemostasis Diagnostics by Test Type - Percentage Breakdown of Value Sales for Prothrombin Test Time (PT), D Dimer, Fibrinogen and Activated Partial Thromboplastin Time for the Years 2015, 2025 & 2030

IV. COMPETITION